Jpmorgan Chase & CO Blueprint Medicines Corp Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,224,654 shares of BPMC stock, worth $113 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,224,654
Previous 1,311,372
6.61%
Holding current value
$113 Million
Previous $124 Million
6.11%
% of portfolio
0.01%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding BPMC
# of Institutions
340Shares Held
62MCall Options Held
987KPut Options Held
578K-
Black Rock Inc. New York, NY6.65MShares$611 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.54MShares$601 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.87MShares$540 Million0.08% of portfolio
-
Wellington Management Group LLP Boston, MA3.24MShares$297 Million0.06% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.46MShares$226 Million8.22% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.49B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...